Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease

An isolated nucleic acid which comprises at least 50 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one allele selected from the group consisting of:
• a. allele G of single nucleotide polymorphism AB+2;
• b. allele G of single nucleotide polymorphism BC+1;
• and
• c. allele C of single nucleotide polymorphism BC+2.

An isolated nucleic acid which comprises at least 15 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one allele selected from the group consisting of:
• a. allele G of single nucleotide polymorphism AB+2;
• b. allele G of single nucleotide polymorphism BC+1;
• and
• c. allele C of single nucleotide polymorphism BC+2.

An isolated nucleic acid which comprises at least 9476 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype selected from the group consisting of:
• a. haplotype G/A at single nucleotide polymorphisms BC+1/AB+3;
• b. haplotype G/G at single nucleotide polymorphisms BC+1/KL+2;
• c. haplotype G/C at single nucleotide polymorphisms BC+1/Q−1;
• d. haplotype G/G at single nucleotide polymorphisms BC+1/S1;
• e. haplotype G/G at single nucleotide polymorphisms BC+1/ST+7;
• f. haplotype G/C at single nucleotide polymorphisms BC+1/V−1;
• g. haplotype G/C at single nucleotide polymorphisms BC+1/V2;
• h. haplotype G/A at single nucleotide polymorphisms KL+2/ST+4;
• and
• i. haplotype T/T at single nucleotide polymorphisms KL+2/L1.

An isolated nucleic acid which comprises at least 9783 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype selected from the group consisting of:
• a. haplotype C/G at single nucleotide polymorphisms AB+2/KL+2;
• b. haplotype C/G at single nucleotide polymorphisms BC+2/F+1;
• c. haplotype C/G at single nucleotide polymorphisms BC+2/KL+2;
• d. haplotype C/G at single nucleotide polymorphisms BC+2/S1;
• e. haplotype C/G at single nucleotide polymorphisms BC+2/S2;
• f. haplotype C/C at single nucleotide polymorphisms BC+2/V−1;
• g. haplotype C/C at single nucleotide polymorphisms BC+2/V7;
• h. haplotype G/G at single nucleotide polymorphisms KL+2/M+1;
• i. haplotype G/T at single nucleotide polymorphisms KL+2/S+1;
• j. haplotype G/A at single nucleotide polymorphisms KL+2/ST+4;
• and
• k. haplotype G/T at single nucleotide polymorphisms KL+2/ST+5.

An isolated nucleic acid which comprises at least 10791 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype selected from the group consisting of:
• a. haplotype Δ/A at single nucleotide polymorphisms AB+4/I1;
• b. haplotype Δ/A at single nucleotide polymorphisms AB+4/L−1;
• c. haplotype Δ/T at single nucleotide polymorphisms AB+4/M+1;
• d. haplotype Δ/C at single nucleotide polymorphisms AB+4/T1;
• e. haplotype Δ/T at single nucleotide polymorphisms AB+4/T+1;
• f. haplotype G/A at single nucleotide polymorphisms KL+2/L−1;
• g. haplotype G/T at single nucleotide polymorphisms KL+2/M+1;
• and
• h. haplotype G/C at single nucleotide polymorphisms KL+2/T1;

An isolated nucleic acid which comprises at least 8812 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype selected from the group consisting of:
• a. haplotype A/C at single nucleotide polymorphisms BC+1/T1;
• and
• b. haplotype A/T at single nucleotide polymorphisms BC+1/T+1.

An isolated nucleic acid which comprises at least 11136 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype selected from the group consisting of:
• a. haplotype T/T at single nucleotide polymorphisms KL+2/S+1;
• b. haplotype T/T at single nucleotide polymorphisms KL+2/ST+5;
• c. haplotype C/T at single nucleotide polymorphisms AB+2/KL+2;
• d. haplotype G/C at single nucleotide polymorphisms AB+3/V−4;
• e. haplotype T/T at single nucleotide polymorphisms BC+2/D1;
• f. haplotype T/C at single nucleotide polymorphisms BC+2/S2;
• g. haplotype T/G at single nucleotide polymorphisms KL+2/V−3;
• h. haplotype T/C at single nucleotide polymorphisms KL+2/V−2;
• i. haplotype A/T at single nucleotide polymorphisms AB+4/T1;
• j. haplotype G/G at single nucleotide polymorphisms KL+2/L−1;
• k. haplotype G/G at single nucleotide polymorphisms KL+2/M+1;
• and
• l. haplotype G/T at single nucleotide polymorphisms KL+2/T1.

An isolated nucleic acid which comprises at least 14134 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype at single nucleotide polymorphisms A−1/AB+2/AB+3/AB+4/BC+1/BC+2/D−2/D−1/D1/F1/F+1/G−1/I1/KL+1/KL+2/L−2/L−1/L1/M+1/Q−1/S1/S2/S+1/ST+4/ST+5/ST+6/ST+7/T1/T2/T+1/T+2/V−4/V−3/V−2/V−1/V2/V3/V4/V5/V6/V7, wherein the haplotype is selected from the group consisting of:
• a. a/c/a/g/g/t/c/c/t/a/g/a/g/c/g/g/g/c/g/c/g/g/t/a/t/c/g/t/c/c/t/c/g/c/c/a/c/t/c/a/c/c
• b. a/g/a/Δ/g/t/c/c/t/a/g/a/g/c/t/g/g/c/g/c/g/g/a/c/c/c/g/t/c/c/t/g/a/t/c/a/c/c/c/a/c/c;
• and
• c. a/c/a/g/g/t/c/c/t/a/g/a/g/c/g/g/g/c/g/c/g/g/t/c/t/c/g/t/c/c/t/c/g/c/c/a/c/t/c/a/c/c.

An isolated nucleic acid which comprises at least 1770 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype at single nucleotide polymorphisms ST+4/ST+5/ST+7/T1/T2/T+1/T+2/V−4/V−3N−2/V−1/V1/V2, wherein the haplotype is selected from the group consisting of:
• a. C/T/G/T/C/C/T/C/G/C/C/A/C;
• b. A/T/G/T/C/C/T/C/G/C/C/A/C;
• and
• c. A/T/A/T/C/C/T/C/G/C/A/A/C.

An isolated nucleic acid which comprises at least 581 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype at single nucleotide polymorphisms V3/V4/V5/V6/V7, wherein the haplotype is selected from the group consisting of:
• a. T/C/A/C/C;
• and
• b. T/G/A/C/G.

An isolated nucleic acid which comprises at least 2021 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype at single nucleotide polymorphisms AB+2/AB+3/AB+4/BC+1, wherein the haplotype is selected from the group consisting of:
• a. G/A/Δ/A;
• and
• b. G/A/G/G.

An isolated nucleic acid which comprises at least 1430 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype at single nucleotide polymorphisms ST+4/ST+5/ST+7N−4, wherein the haplotype is selected from the group consisting of:
• a. A/T/G/C;
• b. C/T/G/C;
• c. C/C/G/C;
• d. A/T/A/C;
• and
• e. C/C/A/C.

An isolated nucleic acid which comprises at least 2285 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype at single nucleotide polymorphisms AB+4/BC+1/BC+2, wherein the haplotype is selected from the group consisting of:
• a. Δ/A/T;
• and
• b. G/G/C.

An isolated nucleic acid which comprises at least 4717 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype at single nucleotide polymorphisms D−1/F1/F+1/G−1/I1/KL+1/KL+2/L−2/L−1/M+1/Q−1/S1/S2/S+1/ST+4, wherein the haplotype is selected from the group consisting of:
• a. C/A/G/A/G/C/G/G/G/G/C/G/G/T/C;
• and
• b. C/A/G/A/G/C/G/G/G/G/C/G/G/T/A.

An isolated nucleic acid which comprises at least 2322 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype at single nucleotide polymorphisms ST+5/ST+7/T2/T+1/T+2/V−4/V−3/V−2/V−1/V1/V2/V3/V4/V5/V6/V7, wherein the haplotype is selected from the group consisting of:
• a. C/A/G/A/G/C/G/G/G/G/C/G/G/T/C;
• and
• b. C/A/G/A/G/C/G/G/G/G/G/G/G/T/A.

An isolated nucleic acid which comprises at least 3859 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype at single nucleotide polymorphisms F+1/KL+2/S+1/ST+4, wherein the haplotype is selected from the group consisting of:
• a. G/G/T/C;
• and
• b. G/G/T/A.

An isolated nucleic acid which comprises at least 6875 contiguous nucleotides of SEQ ID NO:

• 6, and includes at least one haplotype at single nucleotide polymorphisms D1/F1/I1/L1/S1/S2/T1/T2/V1/V2/V3/V4/V5/V6/V7, wherein the haplotype is selected from the group consisting of:
• a. T/G/A/C/G/C/T/C/T/T/C/G/G/C/G;
• b. T/A/G/C/G/G/T/C/A/C/T/C/A/C/G;
• c. T/A/A/C/G/C/C/C/A/C/T/C/A/C/G;
• d. T/A/A/C/G/C/C/T/A/C/C/T/C/G;
• and
• e. T/A/G/C/G/G/T/C/A/C/T/G/A/T/G.

An isolated nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:

• 421-SEQ ID NO:
• 426, SEQ ID NO:
• 463-SEQ ID NO:
• 466, and SEQ ID NO:
• 427-462.

An isolated nucleic acid comprising at least 15 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NO:

• 421-SEQ ID NO:
• 426 and SEQ ID NO:
• 463-SEQ ID NO:
• 466.

An isolated nucleic acid comprising at least 15 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NO:

• 430, SEQ ID NO:
• 434, SEQ ID NO:
• 450, and SEQ ID NO:
• 452 which includes at least allele shown in Table 10.

An isolated nucleic acid comprising at least 15 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NO:

• 430, SEQ ID NO:
• 434, SEQ ID NO:
• 449, SEQ ID NO:
• 432, and SEQ ID NO:
• 451 which includes at least one allele shown in Table 10.